Strides Pharma Science Ltd

Surging past its previous peaks, Strides Pharma Science Ltd touched a fresh 52-week high of Rs 1153.8 on 7 May 2026, propelled by a confluence of bullish technical indicators and sustained price momentum.

Strides Pharma Science Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 April 2026, providing investors with the latest insights into the company’s performance and outlook.

With a 63.32% gain over the past year, Strides Pharma Science Ltd has surged to a fresh 52-week high of Rs 1150 on 28 Apr 2026, outpacing the Sensex which declined by 3.66% over the same period. This milestone reflects a powerful rally fuelled by a confluence of bullish technical indicators and sustained price momentum despite a broadly cautious market backdrop.

With a 67.18% gain over the past year, Strides Pharma Science Ltd has surged to a fresh 52-week high of Rs 1091.8 on 27 Apr 2026, outpacing the Sensex which declined by 2.72% over the same period. This milestone reflects a sustained upward momentum fuelled by a confluence of technical indicators signalling strength across multiple timeframes.

With a 56.26% gain over the past year, Strides Pharma Science Ltd has surged to a fresh 52-week high of Rs 1084.4 on 24 Apr 2026, outpacing the Sensex which declined by 3.48% over the same period. This milestone reflects a sustained rally fuelled by strong technical momentum across multiple indicators despite a broader market downturn.

While the Sensex declined 1.14% on 23 Apr 2026, Strides Pharma Science Ltd surged 7.51%, outperforming its Pharmaceuticals & Biotechnology sector by nearly 5 percentage points. This sharp single-session gain rewrites the short-term narrative for the stock, which has been on a steady upward trajectory over the past week.

Surging past the Rs 1035 mark on 23 Apr 2026, Strides Pharma Science Ltd has reached a fresh 52-week high, marking a 56.56% gain over the past year. This milestone comes amid a backdrop of strong technical momentum, with the stock outperforming its sector and the broader market despite a subdued Sensex.

Strides Pharma Science Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 April 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Strides Pharma Science Ltd has witnessed a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. Despite a modest day decline of 2.73%, the stock’s technical indicators reveal a complex but predominantly positive outlook, supported by improving moving averages and mixed signals from momentum oscillators. This analysis delves into the recent technical parameter changes, evaluating key indicators such as MACD, RSI, Bollinger Bands, and moving averages to provide a comprehensive view of the stock’s near-term trajectory.

The 50-day moving average has crossed above the 200-day moving average for Strides Pharma Science Ltd, signalling a golden cross on 8 Apr 2026. Yet, the stock declined 2.73% on the day the cross formed, while monthly momentum indicators remain mildly bearish. This juxtaposition of signals calls for a detailed examination of the technical and fundamental context behind the crossover.

Strides Pharma Science Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in technical indicators alongside robust quarterly financial performance. The upgrade, effective from 6 April 2026, is underpinned by enhanced technical trends, attractive valuation metrics, and positive financial results, although some long-term fundamental challenges remain.

Strides Pharma Science Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a mildly bullish outlook. This change is underscored by mixed signals from key indicators such as MACD, RSI, and moving averages, reflecting a nuanced market sentiment amid broader sector volatility.

Strides Pharma Science Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 March 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 31 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Strides Pharma Science Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 19 March 2026. This change is primarily driven by a deterioration in technical indicators, despite the company’s robust recent financial performance and attractive valuation metrics. The downgrade reflects a nuanced assessment across four key parameters: Quality, Valuation, Financial Trend, and Technicals.

Strides Pharma Science Ltd has experienced a subtle but notable shift in its technical momentum, moving from a mildly bullish to a mildly bearish stance. This transition is underscored by a combination of technical indicators including MACD, RSI, moving averages, and Bollinger Bands, reflecting a complex interplay of market forces impacting the small-cap pharmaceutical player.

Strides Pharma Science Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting a deterioration in the stock’s medium to long-term momentum and raising concerns about sustained weakness ahead.